Monte Rosa Therapeutics Inc (GLUE) is trading down at $11.11 (-0.98%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | $0 | $75.6M | $123.7M |
| Growth (year over year) | — | — | — | — | — | +63.5% |
| Operating income | −$28.0M | −$72.9M | −$112.4M | −$143.3M | −$81.1M | −$54.2M |
| Operating margin | — | — | — | — | −107.3% | −43.8% |
| Net income | −$35.9M | −$74.0M | −$108.5M | −$135.4M | −$72.7M | −$38.6M |
| Net margin | — | — | — | — | −96.1% | −31.2% |
| EPS (diluted) | −$23.65 | −$2.96 | — | — | — | — |
| Balance sheet | ||||||
| Cash and equivalents | $41.7M | $346.1M | $54.9M | $128.1M | $224.3M | $129.9M |
| Total assets | $49.4M | $366.3M | $342.4M | $303.8M | $438.7M | $448.7M |
| Total liabilities | $30.3M | $18.8M | $71.0M | $124.5M | $215.8M | $215.6M |
| Shareholders' equity | −$48.7M | $347.5M | $271.4M | $179.3M | $222.9M | $233.1M |
| Cash flow | ||||||
| Operating cash flow | −$23.1M | −$59.4M | −$92.5M | −$43.8M | $42.0M | −$22.8M |
| Capital expenditure | $3.39M | $9.73M | $12.9M | $19.0M | $3.99M | $4.70M |
| Free cash flow | −$26.4M | −$69.1M | −$105.4M | −$62.8M | $38.0M | −$27.5M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.22M | — | $84.9M | $23.2M | $12.8M | — | $4.21M | $8.97M |
| Growth (year over year) | — | — | +7882.0% | +394.0% | +38.5% | — | −95.0% | −61.3% |
| Operating income | −$26.5M | — | $44.0M | −$15.6M | −$33.0M | — | −$50.0M | −$49.1M |
| Operating margin | −287.8% | — | 51.9% | −67.1% | −258.3% | — | −1188.5% | −547.8% |
| Net income | −$23.9M | — | $46.9M | −$12.3M | −$27.1M | — | −$44.5M | −$43.4M |
| Net margin | −258.9% | — | 55.2% | −53.0% | −212.1% | — | −1057.1% | −483.9% |
| Balance sheet | ||||||||
| Cash and equivalents | $125.6M | $224.3M | $78.5M | $69.4M | $208.3M | $129.9M | $159.9M | $90.1M |
| Total assets | $315.1M | $438.7M | $393.2M | $359.6M | $459.8M | $448.7M | $736.4M | $691.2M |
| Total liabilities | $109.6M | $215.8M | $118.0M | $91.5M | $214.0M | $215.6M | $214.5M | $203.9M |
| Shareholders' equity | $205.5M | $222.9M | $275.2M | $268.1M | $245.8M | $233.1M | $521.9M | $487.3M |
| Cash flow | ||||||||
| Operating cash flow | −$21.0M | — | −$45.5M | −$34.7M | $100.4M | — | −$37.4M | −$44.1M |
| Capital expenditure | $399.0K | — | $1.59M | $1.70M | $651.0K | — | $1.87M | $4.72M |
| Free cash flow | −$21.4M | — | −$47.1M | −$36.4M | $99.8M | — | −$39.2M | −$48.8M |
| Dividends paid | $0 | — | $0 | $0 | $0 | — | $0 | $0 |
From Monte Rosa Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Filings on SEC EDGAR →
No recent news mentioning Monte Rosa Therapeutics Inc in our feed yet.